文献速递胸部肿瘤放疗放疗物理与技术

肺癌放疗中保护心脏基底部对危及器官剂量的剂量学影响

Dosimetric impact of sparing base of heart on organ at risk doses during lung radiotherapy.
PubMed 文献 · Radiother Oncol · 2024-11-27

单中心对比分析CAA引入前后肺癌放疗患者,引入前组923例(2021年4月至2023年3月),引入后组477例(2023年4月至2024年4月)。引入后计划优化使CAA 1 cc最大剂量低于20次19.5 Gy(或等效生物有效剂量)。CAA作为ARR引入后CAA和整体心脏剂量显著降低,CAA最大剂量(EQD2)中位数从32.0 Gy3降至16.9 Gy3(p<0.001),其他胸部危及器官剂量无显著增加。

要点

  • CAA作为解剖区域风险引入后,CAA最大剂量(EQD2)中位数从32.0 Gy3降至16.9 Gy3(p<0.001)。
  • 引入后计划优化目标为CAA 1 cc最大剂量低于20次19.5 Gy或等效生物有效剂量。
  • 其他胸部危及器官(肺、食管、椎管)剂量未见显著增加。

核心结论

  • 在肺癌放疗计划中引入心脏回避区可显著降低关键心脏区域的剂量,且不损害其他器官的安全性。
  • 该方法有望减少接受放疗的肺癌患者心脏相关不良事件并改善总生存。

研究设计与样本

  • 单中心对比分析,比较CAA于2023年4月引入作为解剖区域风险前后接受肺癌放疗的患者。
  • 引入前组为2021年4月至2023年3月治疗的患者923例,引入后组为2023年4月至2024年4月治疗的患者477例。
  • 引入后组计划优化使CAA 1 cc最大剂量低于20次19.5 Gy或等效生物有效剂量。
  • 比较CAA、心脏、肺、食管和椎管的关键剂量指标。

主要发现

  • CAA作为ARR引入后CAA和整体心脏剂量显著降低,CAA最大剂量(EQD2)中位数从32.0 Gy3降至16.9 Gy3(p<0.001)。
  • 其他胸部危及器官未见剂量显著增加。

关键数值与推荐

  • 引入后组计划优化目标:CAA 1 cc最大剂量低于20次19.5 Gy或等效生物有效剂量。
  • CAA最大剂量(EQD2)中位数:引入前组32.0 Gy3 vs 引入后组16.9 Gy3(p<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Minimising heart exposure during lung radiotherapy (RT) is important due to association between increased cardiac dose and adverse outcomes such as cardiac toxicity and reduced overall survival. This study evaluated the impact of incorporating a cardiac avoidance area (CAA) located at the base of the heart on the dose received by cardiac subregions and thoracic organs at risk. METHODS: A comparative analysis was conducted on patients treated with lung RT at a single centre before and after the CAA was introduced as an anatomical region at risk (ARR) in April 2023. Two patient cohorts were analysed: those treated prior to CAA implementation (April 2021-March 2023, 923 patients) and those treated post implementation (April 2023-March 2024, 477 patients). For the second group, plans were optimised to keep CAA maximum dose to 1 cc below 19.5 Gy in 20 fractions (or equivalent biologically effective dose). Key dose metrics for the CAA, heart, lungs, oesophagus, and spinal canal were compared between the cohorts. RESULTS: The introduction of the CAA as an ARR resulted in significant reductions in CAA and overall heart dose, with median CAA maximum dose (EQD2) decreasing from 32.0 Gy3 to 16.9 Gy3 (p < 0.001). No significant increases in dose were observed for other thoracic organs at risk. CONCLUSIONS: Implementing a cardiac avoidance area in lung RT planning significantly reduces doses to critical heart regions without compromising the safety of other organs. This approach holds promise for reducing cardiac-related adverse events and improving overall survival in patients with lung cancer undergoing RT.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Marchant T, Wood J, Banfill K, et al. Dosimetric impact of sparing base of heart on organ at risk doses during lung radiotherapy. Radiother Oncol. 2024. PMID: 39608678. doi:10.1016/j.radonc.2024.110654

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。